APOE ε4 carrier status and sex differentiate rates of cognitive decline in early‐ and late‐onset Alzheimer's disease
- 17 November 2022
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (5) , 1983-1993
Abstract
Background: We studied the effect of apolipoprotein E (APOE) ε4 status and sex on rates of cognitive decline in early‐ (EO) and late‐ (LO) onset Alzheimer's disease (AD).Method: We ran mixed‐effects models with longitudinal cognitive measures as dependent variables, and sex, APOE ε4 carrier status, and interaction terms as predictor variables in 998 EOAD and 2562 LOAD participants from the National Alzheimer's Coordinating Center.Results: APOE ε4 carriers showed accelerated cognitive decline relative to non‐carriers in both EOAD and LOAD, although the patterns of specific cognitive domains that were affected differed. Female participants showed accelerated cognitive decline relative to male participants in EOAD only. The effect of APOE ε4 was greater in EOAD for executive functioning (p < 0.0001) and greater in LOAD for language (p < 0.0001).Conclusion: We found APOE ε4 effects on cognitive decline in both EOAD and LOAD and female sex in EOAD only. The specific patterns and magnitude of decline are distinct between the two disease variants.Highlights: Apolipoprotein E (APOE) ε4 carrier status and sex differentiate rates of cognitive decline in early‐onset (EO) and late‐onset (LO) Alzheimer's disease (AD). APOE ε4 in EOAD accelerated decline in memory, executive, and processing speed domains. Female sex in EOAD accelerated decline in language, memory, and global cognition. The effect of APOE ε4 was stronger for language in LOAD and for executive function in EOAD. Sex effects on language and executive function decline differed between EOAD and LOAD.Keywords
This publication has 54 references indexed in Scilit:
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-AnalysisDementia and Geriatric Cognitive Disorders, 2010
- Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatmentPharmacogenetics and Genomics, 2009
- The Alzheimer's Disease Centers' Uniform Data Set (UDS)Alzheimer Disease & Associated Disorders, 2009
- Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onsetPsychological Medicine, 2009
- APOE ε4 allele predicts faster cognitive decline in mild Alzheimer diseaseNeurology, 2008
- Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriersThe Pharmacogenomics Journal, 2004
- The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's diseaseAnnals of Neurology, 1997
- Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's diseaseAnnals of Neurology, 1996